Valeritas Holdings, Inc. announced that positive data from its preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion was presented on October 29, 2019 at the 24th World Congress of Neurology held in Dubai, UAE. In the poster presentation titled “Delivery of Apomorphine via Subcutaneous Infusion with the h-Patch Wearable Device,” the data demonstrated that 400ul of a 25mg/ml Apo solution delivered with the h-Patch technology was rapidly absorbed and was detected in plasma within two hours of the start of infusion. Additionally, Apo was still detectable in plasma 24 hours after completion of h-Patch infusion, or 48 hours in total. Valeritas proprietary h-Patch device is a simple all-in-one, fully disposable, drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The Company’s V-Go is the first FDA-approved product that utilizes its h-Patch technology. To date, more than 20 million V-Go insulin delivery devices have been sold in the United States. Treatment of advanced Parkinson’s disease (PD) remains challenging, with fluctuations in motor status often resulting in patients becoming severely handicapped. The magnitude and pattern of the motor response to a single dose of subcutaneously administered Apo are qualitatively comparable to that of oral levodopa; however, side effects of oral dosing (dizziness, nausea, vomiting, etc.) can be problematic.